Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bioverativ Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
True North Therapeutics Raises USD45 Million in Series D Financing 12
True North Therapeutics Raises USD40 Million in Series C Financing 13
True North Therapeutics Raises USD35 Million in Series B Financing 15
True North Therapeutics Raises USD22 Million in Series A Venture Financing 16
Partnerships 18
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18
Licensing Agreements 19
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19
Acquisition 20
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20
Bioverativ Therapeutics Acquires True North Therapeutics 22
Bioverativ Inc – Key Competitors 23
Bioverativ Inc – Key Employees 24
Bioverativ Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance 26
Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance 28
Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance 30
May 03, 2017: Bioverativ Reports First Quarter 2017 Results 32
Corporate Communications 34
May 15, 2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors 34
Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors 35
Government and Public Interest 36
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 36
Product News 38
05/29/2018: Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix’s XTEN technology 38
05/21/2018: Bioverativ Presents Preliminary Phase 1/2a Data on BIVV001, the First Factor VIII Therapy to Break Through the VWF Half-Life Ceiling in Hemophilia A 39
05/14/2018: Bioverativ will highlight commitment to transforming hemophilia care at WFH 2018 world congress 40
Product Approvals 41
Jun 12, 2017: Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A 41
Clinical Trials 42
Jun 18, 2018: Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis 42
Mar 06, 2018: Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease 43
Dec 11, 2017: Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients 44
Nov 01, 2017: Bioverativ to Present New Data on BIVV009 at ASH 2017 Annual Meeting 46
Jan 10, 2017: True North Provides Corporate Update at J.P. Morgan Healthcare Conference 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
Bioverativ Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
True North Therapeutics Raises USD45 Million in Series D Financing 12
True North Therapeutics Raises USD40 Million in Series C Financing 13
True North Therapeutics Raises USD35 Million in Series B Financing 15
True North Therapeutics Raises USD22 Million in Series A Venture Financing 16
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20
Bioverativ Therapeutics Acquires True North Therapeutics 22
Bioverativ Inc, Key Competitors 23
Bioverativ Inc, Key Employees 24
Bioverativ Inc, Other Locations 25
Bioverativ Inc, Subsidiaries 25
List of Figures
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10